{
    "id": 6812,
    "name": "childhood pilocytic astrocytoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:6812",
    "evidence": [
        {
            "id": 14106,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14108,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14109,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14110,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK phosphorylation, resulted in growth inhibition in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18500,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 36% (9/25) of pediatric patients with pilocytic astrocytoma harboring KIAA1549-BRAF (n=18) or BRAF V600E (n=7), with a 2-year progression-free survival of 70%, and 39% (7/18) of the patients harboring KIAA1549-BRAF achieved PR (PMID: 31151904; NCT01089101).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16287,
                    "pubMedId": 31151904,
                    "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14111,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited ERK phosphorylation, resulted in growth inhibition in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14112,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18501,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 36% (9/25) of pediatric patients with pilocytic astrocytoma harboring KIAA1549-BRAF (n=18) or BRAF V600E (n=7), with a 2-year progression-free survival of 70%, and 29% (2/7) of the patients harboring BRAF V600E achieved PR (PMID: 31151904; NCT01089101).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16287,
                    "pubMedId": 31151904,
                    "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}